Form 4: Nuvalent Director Matthew Shair Sells Shares Under 10b5-1 Trading Plan

Director Matthew Shair of Nuvalent, Inc. executed sales of Class A Common Stock on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 28, 2024, Matthew Shair, a director of Nuvalent, Inc., sold shares of Class A Common Stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 21, 2023.
• A total of 1,181 shares were sold at a weighted average price of $91.31, with prices ranging from $90.77 to $91.76.
• An additional 746 shares were sold at a weighted average price of $92.27, with prices ranging from $91.79 to $92.76.
• Furthermore, 73 shares were sold at a weighted average price of $93.11, with prices ranging from $92.90 to $93.21.
• Following these transactions, Mr. Shair directly owns 1,427,197 shares of Class A Common Stock.
• Mr. Shair indirectly owns 224,522 shares through the Matthew D. Shair 2021 Irrevocable Family Trust, for which he has voting and dispositive power.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider trading activity, which is neither inherently positive nor negative. The use of a 10b5-1 plan suggests a planned and compliant approach to selling shares.

Future Outlook

The document does not contain any specific forward-looking statements or guidance from the company.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for corporate insiders to use 10b5-1 plans to sell shares over time to avoid accusations of trading on material non-public information. The impact on the stock price is usually minimal unless the sales are unusually large or frequent.

Comparison to Industry Standards

• Insider selling is a common occurrence in publicly traded companies, especially in the biotech sector where stock options form a significant part of executive compensation.
• The use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.
• Comparable companies like Relay Therapeutics or Black Diamond Therapeutics also see regular Form 4 filings from their executives and directors.
• The size of these transactions is relatively small compared to the overall market capitalization of Nuvalent, suggesting a limited impact on the stock.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely to be negligible.

Key Dates